Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
South Korea · Delayed Price · Currency is KRW 145,100
+6,100 (4.39%)
Feb 9, 2026, 9:18 AM KST
Mezzion Pharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -21,887 | -19,477 | -12,728 | -36,298 | -13,603 | -13,829 |
Depreciation & Amortization | 1,003 | 957.8 | 1,546 | 1,658 | 1,586 | 1,432 |
Loss (Gain) From Sale of Assets | 395.6 | 471.69 | -7.36 | -8.99 | 1.08 | 23.92 |
Asset Writedown & Restructuring Costs | - | - | - | 14,694 | - | - |
Loss (Gain) From Sale of Investments | - | - | - | - | - | -26.76 |
Stock-Based Compensation | 952.54 | 1,193 | 421.61 | 1,293 | 2,535 | 1,132 |
Provision & Write-off of Bad Debts | -2.64 | 162.76 | 87.18 | -20.93 | -124.47 | 66.87 |
Other Operating Activities | 3,823 | 5,282 | -1,128 | 677.64 | -4,327 | 7,026 |
Change in Accounts Receivable | 189.87 | 1,229 | 245.93 | -150.7 | 308.73 | 234.24 |
Change in Inventory | 1,057 | 209.7 | 2,643 | -313.17 | -4,786 | -3,952 |
Change in Accounts Payable | 36.22 | -2,456 | -3,152 | 1,474 | 1,780 | -80.27 |
Change in Other Net Operating Assets | 3,312 | -6,063 | 1,048 | 4,921 | 1,558 | 596.37 |
Operating Cash Flow | -11,121 | -18,489 | -11,023 | -12,075 | -15,071 | -7,377 |
Capital Expenditures | -162.94 | -590.49 | -529.29 | -767.56 | -357.81 | -774.25 |
Sale of Property, Plant & Equipment | 264.54 | - | 77.72 | 9.2 | - | 8.5 |
Cash Acquisitions | - | - | 1,192 | - | - | - |
Sale (Purchase) of Intangibles | -19,644 | -12,888 | -11,329 | -993.47 | -5,825 | -7,182 |
Investment in Securities | 2,876 | 3,000 | -14,967 | 19,157 | -10,151 | 11,509 |
Other Investing Activities | -0 | -0 | 0 | 5.11 | -0 | - |
Investing Cash Flow | -16,174 | -9,576 | -25,555 | 17,410 | -16,334 | 3,561 |
Short-Term Debt Issued | - | 880.09 | 3,226 | 4,832 | 3,744 | 3,841 |
Total Debt Issued | 23,000 | 880.09 | 3,226 | 4,832 | 3,744 | 3,841 |
Short-Term Debt Repaid | - | -1,380 | -3,776 | -4,603 | -3,786 | -3,263 |
Long-Term Debt Repaid | - | -556.43 | -888.69 | -1,157 | -1,071 | -1,085 |
Total Debt Repaid | -620.67 | -1,936 | -4,665 | -5,760 | -4,857 | -4,348 |
Net Debt Issued (Repaid) | 22,379 | -1,056 | -1,439 | -927.79 | -1,114 | -506.62 |
Issuance of Common Stock | 2,087 | 1,726 | 48,653 | 312 | 225.77 | 24,515 |
Other Financing Activities | - | 0 | -0 | - | 20,000 | - |
Financing Cash Flow | 24,466 | 670.32 | 47,214 | -615.79 | 19,112 | 24,008 |
Foreign Exchange Rate Adjustments | 93.73 | 766.18 | 211.86 | 470.01 | 648.86 | 16.75 |
Miscellaneous Cash Flow Adjustments | 0 | - | - | - | - | - |
Net Cash Flow | -2,735 | -26,629 | 10,847 | 5,189 | -11,644 | 20,210 |
Free Cash Flow | -11,284 | -19,080 | -11,553 | -12,842 | -15,429 | -8,151 |
Free Cash Flow Margin | -145.61% | -221.56% | -36.42% | -41.80% | -57.89% | -28.47% |
Free Cash Flow Per Share | -375.38 | -639.74 | -409.10 | -480.39 | -578.14 | -313.46 |
Cash Interest Paid | 284.36 | 293.66 | 220.24 | 26.77 | 7.99 | 9.31 |
Cash Income Tax Paid | 2,522 | 707.61 | 209.5 | 397.25 | 1,531 | 129.23 |
Levered Free Cash Flow | -8,101 | -21,362 | -18,701 | -3,264 | -17,413 | -11,123 |
Unlevered Free Cash Flow | -7,523 | -21,174 | -18,504 | -2,999 | -17,211 | -10,923 |
Change in Working Capital | 4,595 | -7,080 | 785.58 | 5,930 | -1,139 | -3,201 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.